Liteng Lin

1.5k total citations · 1 hit paper
39 papers, 1.1k citations indexed

About

Liteng Lin is a scholar working on Hepatology, Immunology and Molecular Biology. According to data from OpenAlex, Liteng Lin has authored 39 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hepatology, 13 papers in Immunology and 10 papers in Molecular Biology. Recurrent topics in Liteng Lin's work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Nanoplatforms for cancer theranostics (8 papers) and Cancer Mechanisms and Therapy (7 papers). Liteng Lin is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Nanoplatforms for cancer theranostics (8 papers) and Cancer Mechanisms and Therapy (7 papers). Liteng Lin collaborates with scholars based in China, United States and Hong Kong. Liteng Lin's co-authors include Xintao Shuai, Kangshun Zhu, Mingyue Cai, Jingjun Huang, Wensou Huang, Yong Wang, Yongjian Guo, Zecong Xiao, Licong Liang and Xiaoyan Chen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Biomaterials.

In The Last Decade

Liteng Lin

38 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study

2022 117 citations Mingyue Cai, Wensou Huang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Liteng Lin China	18	368	280	268	266	234	39	1.1k
Mingyue Cai China	18	206 0.6×	530 1.9×	187 0.7×	150 0.6×	183 0.8×	53	1.1k
Guanghua Rong China	17	211 0.6×	333 1.2×	160 0.6×	348 1.3×	252 1.1×	27	1.1k
Virender Kumar United States	20	634 1.7×	175 0.6×	169 0.6×	90 0.3×	246 1.1×	40	1.2k
Xu He China	19	358 1.0×	212 0.8×	197 0.7×	79 0.3×	213 0.9×	49	912
Shiji Fang China	21	828 2.3×	238 0.8×	252 0.9×	213 0.8×	234 1.0×	63	1.6k
Amanda M. Clark United States	20	468 1.3×	138 0.5×	374 1.4×	234 0.9×	558 2.4×	38	1.3k
Qichang Zheng China	19	509 1.4×	199 0.7×	100 0.4×	393 1.5×	343 1.5×	43	1.5k
Yitao Ding China	20	434 1.2×	218 0.8×	111 0.4×	47 0.2×	135 0.6×	52	1.3k
Santina Quarta Italy	24	661 1.8×	366 1.3×	48 0.2×	126 0.5×	288 1.2×	64	1.5k
Wenxi Li China	14	473 1.3×	46 0.2×	339 1.3×	151 0.6×	142 0.6×	51	951

Countries citing papers authored by Liteng Lin

Since Specialization

Citations

This map shows the geographic impact of Liteng Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liteng Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liteng Lin more than expected).

Fields of papers citing papers by Liteng Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liteng Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liteng Lin. The network helps show where Liteng Lin may publish in the future.

Co-authorship network of co-authors of Liteng Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Liteng Lin. A scholar is included among the top collaborators of Liteng Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liteng Lin. Liteng Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Yue, Xiaobin Wang, Ye Chen, et al.. (2025). Acid-responsive engineered bacteria with aberrant In-Situ anti-PD-1 expression for post-ablation immunotherapy of hepatocellular carcinoma. Biomedicine & Pharmacotherapy. 186. 118046–118046. 1 indexed citations

Zhou, Jingwen, Jingjun Huang, Yongjian Guo, et al.. (2025). Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study. ImmunoTargets and Therapy. Volume 14. 1187–1200.

Guo, Yongjian, Liteng Lin, Ye Chen, et al.. (2025). Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial. BMC Cancer. 25(1). 205–205. 2 indexed citations

Chen, Gengjia, Liteng Lin, Bo Li, et al.. (2024). Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy. Biomaterials. 309. 122626–122626. 13 indexed citations

Li, Rui, Zhile Liu, Wensou Huang, et al.. (2024). Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal Hypertension. Cellular and Molecular Gastroenterology and Hepatology. 18(4). 101379–101379. 2 indexed citations

Liu, Mingyu, Lulu Xie, Yuying Zhang, et al.. (2023). Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases. Cell Death and Disease. 14(1). 25–25. 18 indexed citations

Chen, Ye, Weiguo Cai, Mingyue Cai, et al.. (2023). Intratumoral Lactate Depletion Based on Injectable Nanoparticles−Hydrogel Composite System Synergizes with Immunotherapy against Postablative Hepatocellular Carcinoma Recurrence. Advanced Healthcare Materials. 13(6). e2303031–e2303031. 17 indexed citations

Chen, Ye, Qianbing Zhang, Xiaobin Wang, et al.. (2023). HBV suppresses macrophage immune responses by impairing the TCA cycle through the induction of CS/PDHC hyperacetylation. Hepatology Communications. 7(11). 11 indexed citations

Wang, Xiaobin, Qiaoyun Zhang, Jingwen Zhou, et al.. (2023). T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 11(2). e006493–e006493. 17 indexed citations

10.

Xie, Lulu, Mingyu Liu, Mingyue Cai, et al.. (2023). Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma. Biomedicine & Pharmacotherapy. 159. 114254–114254. 15 indexed citations

11.

Lin, Liteng, et al.. (2023). High Expression of Ten Eleven Translocation 1 Is Associated with Poor Prognosis in Hepatocellular Carcinoma. Mediators of Inflammation. 2023. 1–22. 8 indexed citations

12.

Xiao, Zecong, Yujun Cai, Jinsheng Huang, et al.. (2023). Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy. Journal of Controlled Release. 356. 360–372. 30 indexed citations

13.

Chen, Ye, Mingyu Liu, Jingjun Huang, et al.. (2021). Sublethal heat stress-induced O-GlcNAcylation coordinates the Warburg effect to promote hepatocellular carcinoma recurrence and metastasis after thermal ablation. Cancer Letters. 518. 23–34. 42 indexed citations

14.

Huang, Jingjun, Wensou Huang, Meixiao Zhan, et al.. (2021). Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. Volume 8. 1445–1458. 27 indexed citations

15.

Lin, Liteng, Yongcheng An, Meixiao Zhan, et al.. (2021). The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. Volume 8. 529–543. 15 indexed citations

16.

Cai, Mingyue, Bo Li, Liteng Lin, et al.. (2020). A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma. Biomaterials Science. 8(12). 3485–3499. 31 indexed citations

17.

Lin, Liteng, Rui Li, Jingjun Huang, et al.. (2020). Nanodrug with ROS and pH Dual‐Sensitivity Ameliorates Liver Fibrosis via Multicellular Regulation. Advanced Science. 7(7). 1903138–1903138. 80 indexed citations

18.

Guo, Yongjian, Liteng Lin, Jingjun Huang, et al.. (2019). LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2. Biomedicine & Pharmacotherapy. 118. 109272–109272. 42 indexed citations

19.

Lin, Liteng, Rui Li, Mingyue Cai, et al.. (2018). Andrographolide Ameliorates Liver Fibrosis in Mice: Involvement of TLR4/NF‐κB and TGF‐β1/Smad2 Signaling Pathways. Oxidative Medicine and Cellular Longevity. 2018(1). 7808656–7808656. 48 indexed citations

20.

Hu, Xiaojun, Chun Wu, Mingyue Cai, et al.. (2016). Hepatocellular Carcinoma Cells Carrying a Multimodality Reporter Gene for Fluorescence, Bioluminescence, and Magnetic Resonance Imaging In Vitro and In Vivo. Academic Radiology. 23(11). 1422–1430. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact